Capricor Therapeutics is taking a victory lap for their phase 2 Duchenne muscular dystrophy (DMD) trial. | Capricor ...

Difficult. Impossible. Agonizing. Worse than voting in the national election. | Difficult. Impossible. Agonizing. Worse than ...

Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest ...

In order to focus its resources on the phase 1 program, dubbed TIDAL-01, the company has today announced a reduction in staff ...

Abbott has received an FDA clearance for the latest version of its sensor-laden catheter used to map out the electrical ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditras | Sanofi has stopped a phase 2 trial of the ...

In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), ...

Eli Lilly is ramping up its efforts to incorporate AI across its business by appointing Thomas Fuchs to the new role of chief ...

Booster Therapeutics has launched with $15 million in seed financing and a mission to take on the current crop of targeted ...

After putting forward preliminary clinical data earlier this year from its neuromodulation implant for reducing chronic ...

Gritstone bio may have left no stone unturned when it came to searching for a financial rescue, but the vaccine biotech has ...

Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...